IMS Health

What IMS Health does

IQVIA (the post-merger entity of IMS Health and Quintiles Transnational, formed in 2016 and rebranded in 2017) operates a global life sciences and healthcare technology platform serving pharmaceutical manufacturers, emerging biopharma, medtech, payers, providers, government, and financial institutions across 100+ countries. Its core offering is the IQVIA Connected Intelligence framework, which integrates 64+ petabytes of proprietary healthcare data (including 1.2B+ non-identified patient records and tracking of 85% of global pharma sales) with AI, analytics, and technology products spanning clinical development (Planning Suite, Site Suite, Patient Engagement Suite, Clinical Trial Financial Suite), real-world evidence (NLP Platform, Health Data Apps & AI), safety and regulatory compliance (IQVIA Vigilance, SmartSolve RIM/eQMS), and commercialization (Field Force Agent, Global Market Insights Agent, Orchestrated Analytics, Next Best Action). Underlying technology includes the IQVIA.ai Platform, Healthcare-grade AI built with NVIDIA, the proprietary Med-R1 8B medical reasoning LLM, and agentic AI products that target clinical, commercial, and real-world operations workflows.

Revenue is generated through four streams: subscription and usage-based licensing of technology and analytics platforms, data licensing and evidence generation services (real-world evidence and data services), project-based and functional service provider arrangements for clinical development (Phase I-III trials), and commercialization services for HCP engagement, promotional effectiveness, and launch strategy. Pricing is quote-based and not publicly disclosed, structured around enterprise agreements with customized terms based on scope, volume, and contract length. Distribution combines dedicated enterprise field sales for large pharmaceutical manufacturers, inside sales for mid-market and renewals, a self-service customer portal for AI-powered tools, and a partner ecosystem of technology and implementation integrators.

The company employs 86,000+ people globally, including 13,000+ technology experts, and supports deep therapeutic specialization across 20+ Centers of Excellence. Strategic priorities evident in the data include embedding AI into enterprise workflows via the NVIDIA partnership, expanding proprietary data assets through targeted acquisitions (historically Cegedim, SDI Health, Privacy Analytics, Q2 Metrics), and consolidating end-to-end capabilities from R&D through commercialization under a single platform-plus-modules architecture.

Name

IMS Health

Legal name

IQVIA Inc.

Website

https://imshealth.com

Company type

Public

Founded year

1974

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

IQVIA is a global life sciences and healthcare technology company providing AI, data analytics, clinical development, and commercialization services to pharmaceutical, biotech, medtech, payer, and government clients across 100+ countries.

Ownership category

akta.pro rank

Product category

Healthcare Data Analytics

NAICS

Professional, Scientific, and Technical Services (54), Software Publishers (5132), Custom Computer Programming Services (541511)

SIC

Services-Health Services (8000)

akta.pro primary industry

De-identification, Tokenization & Privacy-Preserving Data Platforms (HLACAIAK)

akta.pro secondary industries

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB), Randomization & Trial Supply Management (RTSM/IRT/IVRS/IWRS) (HLACAOAC), Adherence, Reminders & Engagement Automation (Medication/Follow-up) (HLACAEAJ), Data Analytics & Business Intelligence Services (BPAHALAC), AI/ML Engineering & Model Development Services (BPAEAHAF)

Keywords

• Pharmaceutical data analytics
• Clinical research services
• Real world evidence
• Life sciences technology
• Commercial intelligence

Headquarters

HQ city

Danbury

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Technology & Analytics Solutions: Subscription and usage-based licensing of technology platforms including clinical trial management, safety, analytics, and AI solutions. Revenue from SaaS platforms, software licenses, and technology services.
2. Real World Evidence & Data Services: Revenue from access to proprietary health data sets, analytics services, and evidence generation for pharmaceutical companies, payers, and providers. Includes data licensing and analytics consulting.
3. Contract Research Services: Full-service clinical development solutions including Phase I-III trials, functional services, and dedicated biotech teams. Project-based and functional service provider arrangements.
4. Commercialization Services: HCP engagement, promotional effectiveness, launch strategy, and brand management services for pharmaceutical commercialization.

Go-to-market motion5 records

Distribution channels4 records

Marketing channels7 records

Core offering

IMS Health (now IQVIA) provides information, services, and technology for the pharmaceutical and healthcare industry, including proprietary healthcare data, AI/ML-driven analytics, technology platforms, contract clinical research services, real world evidence solutions, and commercialization services spanning R&D through market launch. Revenue is generated from subscription and usage-based technology licensing, data monetization, project-based clinical research, and commercialization engagements for life sciences clients globally.

Product overview

IQVIA is a global life sciences and healthcare technology company offering a comprehensive platform-plus-modules architecture. The core offerings include the IQVIA.ai Platform for enterprise AI deployment, IQVIA Healthcare-grade AI technology developed with NVIDIA, and IQVIA Connected Intelligence framework integrating data, analytics, and technology. Clinical solutions span Planning Suite, Grant Plan, Site Suite, Patient Engagement Suite, eCOA, IRT, and Clinical Data Analytics Solutions within technology suites for trial management. Commercial solutions include Field Force Agent and Global Market Insights (GMI) Agent for AI-driven HCP engagement and market intelligence, plus Orchestrated Analytics and Next Best Action for commercial optimization. Compliance products include IQVIA Vigilance Platform, SmartSolve RIM, SmartSolve eQMS, Safety Suite, and Clinical Trial Financial Suite. Real World products feature the Natural Language Processing Platform, Health Data Apps & AI, and patient/profiling solutions. The portfolio collectively enables end-to-end support across research & development, real world evidence, commercialization, and safety & regulatory compliance.

Differentiator

Problem solved

Functional benefit

Brands

• IQVIA.ai Platform: AI platform for scaling AI responsibly across clinical, commercial and real-world operations.
• IQVIA Healthcare-grade AI
• IQVIA Connected Intelligence
• IQVIA Biotech
• IQVIA Medical Reasoning LLM (Med-R1 8B)

Products and services

• IQVIA.ai Platform Enterprise AI platform that enables life sciences users to work more efficiently, make better decisions, and scale AI responsibly across clinical, commercial, and real-world operations. Targeted at pharmaceutical, biotech, and healthcare organizations.
• IQVIA Healthcare-grade AI AI technology engineered specifically for life sciences with higher precision, speed, and trust standards than general-purpose AI, built in collaboration with NVIDIA. For life sciences and healthcare organizations requiring regulatory-grade reliability.
• IQVIA Connected Intelligence Framework that brings together data, expertise, AI, analytics, and technology to address unique customer needs across life sciences.
• Planning Suite Clinical trial planning solution within IQVIA's orchestrated clinical trials portfolio, supporting protocol design and study planning for pharmaceutical and biotech sponsors.
• Grant Plan Clinical trial financial planning and budgeting tool within the Clinical Trial Financial Suite, used by sponsors to manage trial budgets.
• Site Suite Clinical trial site management solution that increases transparency, improves communications, and reduces administrative burden from start to finish for sponsors and investigator sites.
• Clinical Trial Payments AI-powered clinical trial payment management solution within the Clinical Trial Financial Suite for managing site payments.
• Patient Engagement Suite Comprehensive patient engagement solution for clinical trials that improves operations, elevates experience, and drives better patient outcomes for sponsors and trial participants.
• Electronic Clinical Outcome Assessment (eCOA) Electronic Clinical Outcome Assessment solution providing digital capture of high-quality patient data to streamline reporting and improve accuracy in clinical trials.
• Interactive Response Technology (IRT) Interactive Response Technology for patient randomization and trial supply management in clinical trials.
• Clinical Data Analytics Solutions Analytics solutions for clinical trial data management and insights, supporting data-driven decisions during study execution.
• IQVIA Vigilance Platform Pharmacovigilance platform powered by human expertise and advanced technology for speed, accuracy, and global compliance with drug safety regulations.
• SmartSolve RIM Regulatory information management system that streamlines global quality assurance and regulatory affairs processes for life sciences companies.
• SmartSolve eQMS Electronic quality management system supporting compliance, efficiency, and faster market access for life sciences companies.
• Safety Suite AI-powered pharmacovigilance suite with automation, global expertise, and real-time safety insights for life sciences companies.
• Clinical Trial Financial Suite AI-powered platform unifying budgeting, contracting, forecasting, and payments for streamlined clinical trial financial management across sponsors.
• Quality Management and Regulatory Suite Suite for streamlining global quality assurance and regulatory affairs processes with AI-enabled QMS and RIM capabilities for compliance, efficiency, and faster market access.
• Field Force Agent AI-powered assistant that helps life sciences field teams plan and execute high-impact, compliant HCP engagements by delivering real-time insights, built on IQVIA OneKey HCP/HCO reference data.
• Global Market Insights (GMI) Agent AI agent providing a unified view of the global market landscape by analyzing market shifts using real-time HCP sentiment, optimizing launch strategies with competitive intelligence, and identifying trends across sales and promotional channels.
• Natural Language Processing Platform Advanced Natural Language Processing platform for extracting insights at scale from unstructured text with fast, accurate, proven capabilities for real world evidence generation in life sciences.
• Health Data Apps & AI Solutions providing access to the largest agnostic health data catalog to streamline research and real world data discovery for life sciences and healthcare organizations.
• IQVIA AI Assistant Conversational AI interface providing instant insights from a powerful conversational interface for life sciences users.
• IQVIA Patient Experience Platform Platform delivering personalized, technology-enabled experiences that improve patient satisfaction, adherence, and outcomes for life sciences companies.
• Orchestrated Analytics AI-powered analytics solution for commercial effectiveness and precision insights across commercial operations.
• Next Best Action AI-driven recommendation engine for determining optimal next actions in HCP and patient engagement for commercial teams.

Quantifiable outcome

• 46% faster clinical trial site identification
• +1 more outcomes

Named customers3 records

Segments7 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature7 records

Partnerships

Three partnerships are on record, tiered core.

• Boehringer IngelheimcoreStrategic or Co-development Partner · 1 January 2026Strategic long-term global commercial data foundation transformation collaboration. Multi-year partnership focused on transforming Boehringer Ingelheim's commercial operations using IQVIA's data and analytics capabilities.
• VeevacoreStrategic or Co-development Partner · 1 August 2025Long-term clinical and commercial partnerships including resolution of all previous disputes. Establishes ongoing collaboration between IQVIA and Veeva for life sciences technology integration.
• NVIDIAcoreTechnology or Integration · 1 January 2025Strategic collaboration to accelerate Healthcare-grade AI development. IQVIA's new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. This partnership creates new ways for customers to accelerate their efforts to improve patient outcomes.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Veeva Systems: Veeva provides cloud-based life sciences software spanning clinical, regulatory, and commercial functions. It directly competes with IQVIA across eCOA, IRT, RIM, CRM, and commercial data, and is a stated long-term IQVIA partner following the resolution of prior disputes.
• ICON plc: ICON is one of the largest global contract research organizations, offering Phase I–IV clinical development, labs, and decentralized trial services. It competes head-to-head with IQVIA's CRO and biotech services, and with its PRA Health Sciences acquisition also expanded into clinical technology and data analytics.
• Labcorp (including Fortrea): Labcorp operates a leading global CRO (formerly Covance) plus central laboratory and diagnostic businesses. It competes with IQVIA across clinical trials, central labs, and real-world data, and spun out Fortrea as a dedicated CRO competitor.
• Medidata Solutions (Dassault Systèmes): Medidata, owned by Dassault Systèmes, is a leading clinical trials technology platform covering EDC, eCOA, RTSM/IRT, and clinical analytics. It directly competes with IQVIA's orchestrated clinical trials suite, including eCOA and IRT products.
• Charles River Laboratories: Charles River provides research models, preclinical and clinical lab services, and manufacturing support to biopharma. It competes with IQVIA's preclinical, lab, and contract research services, particularly in early-stage drug development.
• Syneos Health: Syneos is a fully integrated biopharmaceutical solutions organization combining a CRO with commercial and patient engagement services. It competes with IQVIA across both clinical operations and commercialization offerings for pharma and biotech customers.
• PPD (Thermo Fisher Scientific): PPD, now part of Thermo Fisher Scientific, is a major global CRO offering clinical development, lab, and real-world evidence services. It competes with IQVIA's CRO and biotech services and is part of a broader life sciences tools platform.

Emerging players

• Palantir Technologies: Palantir's Foundry and AIP platforms are increasingly used by large pharma and health systems for clinical, commercial, and real-world data analytics. It is an emerging competitor in healthcare data infrastructure and AI-driven decisioning, overlapping with IQVIA's analytics and AI offerings.

Broad incumbents

• Oracle Health (formerly Cerner): Oracle Health provides large-scale health IT and real-world data infrastructure for providers, payers, and life sciences. It overlaps with IQVIA in clinical research data, RWE, and health-data platforms, and brings substantially larger enterprise software and cloud scale.
• SAS Institute: SAS provides advanced analytics, AI, and clinical analytics solutions widely used in life sciences and healthcare. While broader and more horizontal than IQVIA, it competes in the same healthcare data analytics and AI/ML services category, particularly for biopharma and payer customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/imshealth
• Xx.com/IMSHealth
• LinkedInlinkedin.com/company/ims-health

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A29 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMS Health